Systemic Sclerosis Clinical Trials

61 recruiting

Systemic Sclerosis Trials at a Glance

117 actively recruiting trials for systemic sclerosis are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Phase 1 with 35 trials, with the heaviest enrollment activity in Ann Arbor, Paris, and New York. Lead sponsors running systemic sclerosis studies include Beijing GoBroad Hospital, China Immunotech (Beijing) Biotechnology Co., Ltd., and Hacettepe University.

Browse systemic sclerosis trials by phase

Treatments under study

About Systemic Sclerosis Clinical Trials

Looking for clinical trials for Systemic Sclerosis? There are currently 61 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Systemic Sclerosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Systemic Sclerosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 117 trials

Recruiting
Phase 1

A Study of AZD0120 in Autoimmune Diseases

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis
AstraZeneca27 enrolled18 locationsNCT07295847
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled18 locationsNCT06308978
Recruiting
Not Applicable

Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases

Rheumatoid ArthritisSystemic Lupus ErythematosusDermatomyositis+1 more
The First Affiliated Hospital with Nanjing Medical University72 enrolled1 locationNCT07558850
Recruiting
Phase 1Phase 2

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

SclerodermaSystemic Sclerosis
Cabaletta Bio12 enrolled10 locationsNCT06328777
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

Systemic Sclerosis (SSc)
argenx81 enrolled74 locationsNCT06655155
Recruiting
Phase 2

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics85 enrolled5 locationsNCT07287670
Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting
Early Phase 1

MTS109 in Patients With Refractory Autoimmune Diseases

Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic Sclerosis (SSc)
Shanghai Changzheng Hospital15 enrolled1 locationNCT07526350
Recruiting
Phase 1Phase 2

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Systemic Lupus ErythematosusLupusAutoimmune Disorders+2 more
M.D. Anderson Cancer Center47 enrolled2 locationsNCT06434363
Recruiting
Phase 1Phase 2

Controlling Hyperactive Immunity With Long-lived Lymphocytes

Rheumatoid Arthritis (RA)Autoimmune Rheumatologic DiseaseDiffuse Cutaneous Systemic Sclerosis+1 more
Quell Therapeutics Limited16 enrolled6 locationsNCT07473154
Recruiting
Early Phase 1

A Study of CC312 for Relapsed/Refractory Autoimmune Diseases

SLE - Systemic Lupus ErythematosusSSc-Systemic SclerosisIIM- Idiopathic Inflammatory Myopathies
CytoCares Inc6 enrolled1 locationNCT07193810
Recruiting
Phase 3

Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease

Interstitial Lung DiseaseSystemic Sclerosis
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland86 enrolled1 locationNCT06297096
Recruiting
Phase 1

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Systemic SclerosisIdiopathic Inflammatory MyopathySystemic Lupus Erythematosus (With and Without Nephritis)
Allogene Therapeutics66 enrolled13 locationsNCT07085104
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Idiopathic Inflammatory MyopathiesSystemic Sclerosis
Nkarta, Inc.144 enrolled15 locationsNCT06733935
Recruiting
Phase 2

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary FibrosisInterstitial Lung DiseasePulmonary Fibrosis+4 more
Avalyn Pharma Inc.375 enrolled152 locationsNCT06329401
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Phase 2

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

Systemic Sclerosis
Galderma R&D162 enrolled3 locationsNCT07047690
Recruiting
Phase 2

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis
Hospital for Special Surgery, New York30 enrolled1 locationNCT03844061
Recruiting
Not Applicable

Systemic Sclerosis DIet for GastrointESTinal Symptoms

Systemic Sclerosis (SSc)
University of Michigan60 enrolled1 locationNCT07402226
Recruiting

Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD

SSc-Systemic Sclerosis
University of Patras35 enrolled1 locationNCT07491523